Efficacy outcomes by gene mutations
| Subgroup . | Patients, n . | ORR % (95% CI) . | DOR median, mo (95% CI) . | PFS median, mo (95% CI) . |
|---|---|---|---|---|
| ATM | ||||
| WT | 36 | 83.3 (67.2-93.6) | NE (30.6-NE) | NE (14.7-NE) |
| Mutated | 18 | 94.4 (72.7-99.9) | 24.9 (13.8-NE) | 24.8 (16.4-NE) |
| KMT2D | ||||
| WT | 38 | 86.8 (71.9-95.6) | NE (16.5-NE) | 33.1 (16.6-NE) |
| Mutated | 16 | 87.5 (61.7-98.4) | NE (10.2-NE) | NE (5.4-NE) |
| BIRC3 | ||||
| WT | 48 | 87.5 (74.8-95.3) | NE (16.5-NE) | 33.1 (16.7-NE) |
| Mutated | 6 | 83.3 (35.9-99.6) | NE (13.8-NE) | NE (2.5-NE) |
| NOTCH1 | ||||
| WT | 48 | 91.7 (80.0-97.7) | NE (19.5-NE) | NE (16.8-NE) |
| Mutated | 6 | 50.0 (11.8-88.2) | 14.0 (2.8-NE) | 4.1 (0.8-NE) |
| CCDN1 | ||||
| WT | 51 | 86.3 (73.7-94.3) | NE (16.5-NE) | NE (16.7-NE) |
| Mutated | 3 | 100.0 (29.2-100.0) | 30.6 (5.8-NE) | 33.1 (8.4-NE) |
| BCL10/CARD11 | ||||
| WT | 51 | 90.2 (78.6-96.7) | NE (16.5-NE) | NE (16.8-NE) |
| Mutated | 3 | 33.3 (0.8-90.6) | NE (NE-NE) | 2.9 (0.8-NE) |
| Subgroup . | Patients, n . | ORR % (95% CI) . | DOR median, mo (95% CI) . | PFS median, mo (95% CI) . |
|---|---|---|---|---|
| ATM | ||||
| WT | 36 | 83.3 (67.2-93.6) | NE (30.6-NE) | NE (14.7-NE) |
| Mutated | 18 | 94.4 (72.7-99.9) | 24.9 (13.8-NE) | 24.8 (16.4-NE) |
| KMT2D | ||||
| WT | 38 | 86.8 (71.9-95.6) | NE (16.5-NE) | 33.1 (16.6-NE) |
| Mutated | 16 | 87.5 (61.7-98.4) | NE (10.2-NE) | NE (5.4-NE) |
| BIRC3 | ||||
| WT | 48 | 87.5 (74.8-95.3) | NE (16.5-NE) | 33.1 (16.7-NE) |
| Mutated | 6 | 83.3 (35.9-99.6) | NE (13.8-NE) | NE (2.5-NE) |
| NOTCH1 | ||||
| WT | 48 | 91.7 (80.0-97.7) | NE (19.5-NE) | NE (16.8-NE) |
| Mutated | 6 | 50.0 (11.8-88.2) | 14.0 (2.8-NE) | 4.1 (0.8-NE) |
| CCDN1 | ||||
| WT | 51 | 86.3 (73.7-94.3) | NE (16.5-NE) | NE (16.7-NE) |
| Mutated | 3 | 100.0 (29.2-100.0) | 30.6 (5.8-NE) | 33.1 (8.4-NE) |
| BCL10/CARD11 | ||||
| WT | 51 | 90.2 (78.6-96.7) | NE (16.5-NE) | NE (16.8-NE) |
| Mutated | 3 | 33.3 (0.8-90.6) | NE (NE-NE) | 2.9 (0.8-NE) |
NE, not estimable; WT, wild-type.